M+G LS -,05/ GB00BKFB1C65 /
2024-11-06 6:03:25 PM | Chg. +0.0300 | Volume | Bid2024-11-06 | Ask2024-11-06 | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
2.3800EUR | +1.28% | 172 Turnover: 417.4420 |
2.3380Bid Size: 2,200 | 2.3800Ask Size: 2,200 | 5.75 mill.EUR | - | - |
GlobeNewswire
08-31
Junshi Biosciences Announces 2024 Interim Financial Results and Provides Corporate Updates
GlobeNewswire
08-28
Nxera Pharma Notes Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568
GlobeNewswire
08-27
AMN Healthcare Introduces Strategic Partnership Solutions – First In-House Full-Service Language Ser...
GlobeNewswire
08-22
Mount Sinai Health System Partners with Pickleball Organization CityPickle to Promote Health, Physic...
GlobeNewswire
08-08
Association of Corporate Counsel Launches New Well-being Toolkit for In-house Lawyers
GlobeNewswire
08-07
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
GlobeNewswire
08-07
Intra-Cellular Therapies Reports Second Quarter 2024 Financial Results, Provides Corporate Update an...
GlobeNewswire
08-01
Elevar Therapeutics Granted Orphan Medicinal Product Designation by the European Medicines Agency fo...
GlobeNewswire
07-29
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Eva...
GlobeNewswire
07-26
Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and K...
GlobeNewswire
07-23
Aledade and eClinicalWorks Partner to Enhance Physician Experience through Ambient Listening Technol...
GlobeNewswire
07-15
NYSIF Expands Innovative Claim Mobile App; Now Available for Disability Benefits and Paid Family Lea...
GlobeNewswire
07-09
Elevar Therapeutics Reports Plans for Near-Term Resubmission of NDA for First-Line Treatment Option ...
GlobeNewswire
07-09
Strong Proof-of-Concept Data from Phase 2 Trial of PDE10A Inhibitor (CPL’36), a Novel Oral Antipsych...